Detalhe da pesquisa
1.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1189, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32347358
2.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1177-1187, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32140762
3.
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
J Oncol Pharm Pract
; 25(3): 551-557, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29207939
4.
Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.
Acta Oncol
; 57(6): 867-872, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241410
5.
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
Clin Lung Cancer
; 22(3): e379-e389, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653295
6.
Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting.
JACC CardioOncol
; 2(3): 491-502, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34396256